Intellia Therapeutics Inc（NTLA）财务数据NTLAIntellia Therapeutics Inc

Evaluating the bottom line, Intellia Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1472.25%, while the net margin is -1392.27%. These profitability ratios, combined with a Return on Equity (ROE) of -55.44%, provide a clear picture of how effectively NTLA converts its operational activities into shareholder value.

In the context of the broader market, NTLA competes directly with industry leaders such as ZBIO and NUVB. With a market capitalization of $1.60B, it holds a significant position in the sector. When comparing efficiency, NTLA's gross margin of 100.00% stands against ZBIO's 100.00% and NUVB's 86.54%. Such benchmarking helps identify whether Intellia Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Intellia has reported consistent losses, with a net income of -106634000 USD in Q2 2026 and a gross margin of 100%, indicating no revenue generation despite high costs. The forward P/E ratio is 0, reflecting a lack of earnings expectations.